Brian Jonas, MD, Discusses FDA Approval of Venclexta® in Combination for the Treatment of Newly Diagnosed AML
By Rob Dillard - Last Updated: April 13, 2023Brian Jonas, MD, PhD, FACP sat down with DocWire News Discusses FDA Approval of Venclexta® in combination with with azacitidine, or decitabine, or low-dose cytarabine for the Treatment of Newly Diagnosed AML.
Advertisement
Advertisement
Related Posts
Parkinson's disease and melanoma are believed to be linked due to DNA double-strand break repair thus cell proliferation.
Dr. Eric Dr. Bergson about the importance of head and neck cancer awareness, how to integrate screening into routine care.
AI analysis provides an opportunity for timely intervention to improve the ability to swallow as well as quality of life.
Euphorbis tirucalli leaf extract has the potential ability to inhibit EBV-positive cell proliferation.
A study has uncovered a novel method to enhance immunotherapy for melanoma by targeting a protein known as MARCO.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.